<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000543123">
  <TermName>anti-CD22 immunotoxin</TermName>
  <TermPronunciation>(AN-tee … IH-myoo-noh-TOK-sin)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A monoclonal antibody linked to a toxic substance. It is being studied in the treatment of some types of B-cell cancer. Anti-CD22 immunotoxin is made in the laboratory. It binds to CD22, a protein on the surface of normal B cells and B-cell tumors, and kills the cells.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000718166" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;anti-CD22 immunotoxin&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000718168" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;inmunotoxina anti-CD22&quot;" language="es" id="_4"/>
  <SpanishTermName>inmunotoxina anti-CD22</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Anticuerpo monoclonal unido a una sustancia tóxica. Está en estudio para el tratamiento de algunos tipos de cáncer de células B. La inmunotoxina anti-CD22 se produce en el laboratorio. Se une a la CD22, una proteína de la superficie de las células B normales y de las células B tumorales, y destruye las células.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2007-08-20</DateFirstPublished>
</GlossaryTerm>
